We read with interest the recent results of a study by Neumann et al. 1 relating to the use of the cyclosporine A and mycophenolate mofetil (CSA/MMF) combination in stem cell transplantation from HLA identical siblings following myeloablative conditioning. The successful use of CSA combined with MMF in the prevention of graftversus-host disease (GvHD) was described in allogeneic stem cell transplantation (allo-SCT) following nonmyeloablative conditioning regimens. 2, 3 Information as to the use of this combination in classical myeloablative SCT is limited. The well-known adverse effects of methotrexate (MTX), especially its acute gastrointestinal (GIT) toxicity, may be a significant factor in the increased peritransplant morbidity, leading to increased medical costs and prolonged hospitalisation. It is thus also a factor that negatively affects quality of life. This explains the attempts to reduce MTX doses or to replace it with another immunosuppressive agent. As the study conducted by Neumann et al. does not include any information about the incidence of GIT toxicity including mucositis, we would like to present the experience of our centre, comparing both immunosuppressive regimens (CSA/MTX vs CSA/MMF) in sibling and MUD allo-SCT, 4 with different results than those published by Neumann et al.
We retrospectively analysed the effect of substituting MMF for MTX (in combination with CSA) on the development of GIT toxicity, engraftment and the incidence of acute GvHD. Mucositis was evaluated according to the standard WHO classification. The statistical analysis was conducted using the double-sided Chi-square test. We evaluated a total of 46 patients: n ¼ 20 in the CSA/MTX group and n ¼ 26 in the CSA/MMF group. In both groups, the conditioning regimen included total body irradiation (TBI): in the CSA/MTX group (55%), in the CSA/MMF group (50%). In most patients the graft consisted of mobilised peripheral stem cells. All patients received intravenous CSA, 3 mg/kg/day and intravenous MTX, 15 mg/m 2 on day þ 1 and 10 mg/m 2 on days þ 3, þ 6, þ 11 in the CSA/MTX group or MMF 15 mg/kg twice daily orally or intravenously depending on patient tolerance in the CSA/MMF group.
The groups of patients and results are detailed in Table 1 . The incidence of mucositis was lower overall in the CSA/ MMF group compared to the group receiving CSA/MTX. In the CSA/MMF group, no cases of severe mucositis were observed, in contrast to the CSA/MTX group, where the incidence of mucositis grade IV was 35% (n ¼ 7). This observation also corresponds to the overall longer hospital stay, greater opioid requirements and longer duration of total parenteral nutrition in the CSA/MTX group. The average number of days to granulocyte engraftment did not differ in the two arms (the median number of days for CSA/MTX was 24, and for CSA/MMF 22). The incidence of acute GvHD did not differ between the two groups (CSA/MMF 32% vs CSA/MTX 40%).
The results of our study show that CSA in combination with MMF is an immunosuppressive regimen comparable to the 'gold standard' CSA/MTX regimen for acute GvHD prophylaxis in ablative SCT, and these findings are in agreement with the results published by Neumann et al. 1 and Bolwell et al. 5 In contrast to these studies our study does not support the results of earlier granulocyte engraftment in the CSA/MMF group. The main difference observed in our analysis, and that of Kiehl et al. 6 who reported similar data, is the significant decrease in acute GIT toxicity in the CSA/ MMF group. Although the cost of MMF is higher than MTX, the final cost of transplantation may be lower than when using CSA/MTX, which is associated with prolonged hospitalization (31 vs 38 days) and the need of more intensive supportive therapy (Table 1) .
Since the only available data come from single-centre, retrospective studies, a multicentre, prospective study using mobilised PBSC should be conducted in the future in order to allow definitive conclusions to be drawn. D Pohlreich, A Vitek, J Maalouf and P Cetkovsky Institute of Hematology and Blood Transfusion, BMT Unit, U nemocnice 1, Prague, Czech Republic E-mail: david.pohlreich@uhkt.cz
Pohlreich and co-workers report a decreased incidence and severity of acute gastrointestinal toxicity when substituting Methotrexate (MTX) with Mycofenolate Mofetil (MMF) for the prevention of graft-versus-host disease in stem cell transplantation following myeloablative conditioning. They do not find a significant difference in time to engraftment between patient groups. In our study, we concluded that the toxicity profile of Cyclosporine A (CSA)/MMF in comparison to CSA/ MTX is superior as mainly reflected by the shorter time to engraftment. 1 Owing to the fact that we referred to retrospective data, we did not report in detail the severity of mucositis among patients treated at our center. Documentation was not standardized and supportive care improved during the study period, making a direct comparison difficult. However, we also observed a decreased incidence of severe mucositis and length of hospitalization, which can be interpreted as a consequence of the substitution of MMF for MTX. In addition to a favorable gastrointestinal toxicity profile, the accelerated engraftment, which is associated with the resolution of mucositis in most cases, may be responsible for these differences.
With respect to engraftment, Pohlreich and co-workers did not find a significant difference between patients receiving CSA/MMF or CSA/MTX. This may be explained by several details of their data. The relatively small patient groups included heterogeneous patient populations with respect to age, diagnosis, donor type and probably disease stage and transplant source. First, the main patient group receiving CSA/MTX had chronic myelogenous leukemia (65%) whereas this group represented only 38% in the CSA/MMF group. Second, HLA-identical sibling transplants were mixed with MUD transplants favoring the CSA/MTX group. It is very likely that the proportions of peripheral blood stem cells (PBSCs) and bone marrow are not equally balanced which may lead to a longer time to hematopoietic reconstitution in the group including more marrow transplants. Moreover, numbers of transplanted CD34 þ cells may be different between groups as well as the number of previous therapies.
To avoid this bias, we focused our analysis on welldefined patient groups and looked only at patients with leukemia receiving transplants from HLA-identical siblings in early disease stages. A shorter time to hematopoietic reconstitution was evident, even if only patients receiving mobilized PBSCs were analyzed. This is in line with the data of Bolwell et al.
2 who reported similar results from a
